Finance

Lists
GNMSF:OTCMKTS
Genmab A/S
367,00 US$
0,00%
(0,00) 1D
9 ოქტ, 10:28:36 GMT-4  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for GNMSF...
Mkt. cap
22,98 მლრდ.
Avg. vol.
1,37 ათ.
Volume
180,00
52-wk high
396,97 US$
52-wk low
232,50 US$
Beta
0,73
Shares outstanding
62,41 მლნ.
No. of employees
3 ათ.
Mkt. cap
22,98 მლრდ.
Avg. vol.
1,37 ათ.
Volume
180,00
52-wk high
396,97 US$
52-wk low
232,50 US$
Beta
0,73
Shares outstanding
62,41 მლნ.
No. of employees
3 ათ.
News stories
From web sources and news partners
TipRanks
TipRanks
·
4 საათის წინ
Genmab Reports USD 4.2 Billion in Q3 2026 DARZALEX Net Sales
Profile
Genmab A/S is a Danish biotechnology company, founded in February 1999 by Florian Schönharting, at the time managing director of BankInvest Biomedical venture fund. The company is based in Copenhagen, Denmark – internationally, it operates through the subsidiaries Genmab B.V. in Utrecht, The Netherlands, Genmab U.S., Inc. in Princeton, New Jersey, US, Genmab K.K. in Tokyo, Japan, Genmab Germany GmbH in München, Germany and Genmab Co., Ltd. in Suzhou, China. Genmab is listed on the Copenhagen Stock Exchange in Denmark, with American depositary receipts traded on the NASDAQ in the US. Wikipedia
About Genmab A/S
CEOJan G. J. van de Winkel
Employees3,12 ათ.
Founded11 ივნ. 1998
Headquarters-
Sector-
Websitegenmab.com
Previous reportsAll values in DKK
Loading Previous Earnings...
Revenue
Net income
All values in DKK
დეკ. 2023
მარ. 2024
ივნ. 2024
სექ. 2024
Revenue
4,68 მლრდ.
4,14 მლრდ.
5,40 მლრდ.
5,54 მლრდ.
Cost of goods sold
-
-
-
273,00 მლნ.
Cost of revenue
-
-
-
273,00 მლნ.
Research and development expenses
-
-
-
2,28 მლრდ.
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
-
-
-
865,00 მლნ.
Operating expense
-
-
-
3,15 მლრდ.
Total operating expenses
-
-
-
3,42 მლრდ.
Operating income
-
-
-
2,12 მლრდ.
Other non operating income
-
-
-
-
EBT including unusual items
-
-
-
1,72 მლრდ.
EBT excluding unusual items
-
-
-
1,59 მლრდ.
Income tax expense
-
-
-
453,00 მლნ.
Effective tax rate
-
-
-
26,35%
Other operating expenses
-
-
-
-
Net income
-
-
-
1,27 მლრდ.
Net profit margin
-
-
-
22,85%
Earnings per share
9,67
-
-
19,81
Interest and investment income
-
-
-
162,00 მლნ.
Interest expense
-
-
-
-18,00 მლნ.
Net interest expenses
-
-
-
144,00 მლნ.
Depreciation and amortization charges
-
-
-
-
EBITDA
-
-
-
2,20 მლრდ.
Gain or loss from assets sale
-
-
-
-
AI content may include mistakes. Learn more
Google აპები